Treatment of chronic myelogenous leukemia: Current status and investigational options

Blood

Volumn 87, Issue 8, 1996, Pages 3069-3081

  Kantarjian, Hagop M ^a   O'Brien, Susan ^a   Anderlini, Paolo ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CYTARABINE; HOMOHARRINGTONINE; HYDROXYUREA; BIOLOGICAL RESPONSE MODIFIER; HARRINGTONINE DERIVATIVE;

ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEPRESSION; DRUG INDUCED DISEASE; DRUG RESPONSE; FATIGUE; HUMAN; INSOMNIA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CONTROLLED CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MYELOID LEUKEMIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; SALVAGE THERAPY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; BONE MARROW TRANSPLANTATION; CYTARABINE; HARRINGTONINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0030584729     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.8.3069.bloodjournal8783069     Document Type: Review

References (92)

1. Bortin M, Horowitz M, Rowlings P, et al: Report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 12:97, 1993
2. Gratwohl A, Hermans J, Niederwieser D, et al: Bone marrow transplantation for chronic myeloid leukemia: Long-term results Bone Marrow Transplant 12:509, 1993
3. Horowitz MM, Przepiorka D, Champlin RE, et al: Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood 74:2771, 1992
4. Goldman J, Szydlo R, Horowitz M, et al: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235, 1993
5. Arcese W, Goldman JM, D'Arcangelo E, et al: Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 82:3211, 1993
6. Clift R, Appelbaum F, Thomas E: Bone marrow transplantation for chronic myelogenous leukemia. Blood 83:2752, 1994
7. Clift RA, Appelbaum FR, Thomas ED: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954, 1993
8. Snyder D, Negrin R, O'Donnell M, et al: Fractionated total-body irradiation and high dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood 84:1672, 1994
9. Biggs J, Szer J, Crilley P, et al: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BUCy2. Blood 82:1352, 1992
10. Storb R, Deeg HJ, Pepe M, et al: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia. Long-term follow-up of a controlled trial. Blood 73:1729, 1989
11. Nash RA, McSweeney PA, Storb R, et al: FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from phenotypically HLA-identical unrelated donors. Blood 84:394a, 1994 (abstr, suppl 1)
12. Goodrich JM, Bowden RA, Fisher L, et al: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 118:173, 1993
13. Goodrich JM, Mori M, Gleaves CA, et al: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601, 1991
14. Clift RA, Buckner CD, Appelbaum FR, et al: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase. A randomized trial of two irradiation regimens. Blood 77:1660, 1991
15. Clift RA, Buckner CD, Thomas ED, et al: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994
16. Anderson JE, Appelbaum FR, Storb R, Anasetti C: Busulfan and cyclophosphamide with or without total body irradiation as preparative regimens for patients undergoing allogeneic bone marrow transplantation for myelodysplastic syndrome. Blood 82:377a, 1993 (abstr, suppl 1)
17. Kolb HJ, Mittermuller J, Clemm Ch, et al: Donor leukocyte transfusions for treatment of recurent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990
18. Kolb HJ, Schattenberg A, Goldman J, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995
19. Antin JH: Graft-versus-leukemia: No longer an epiphenomenon. Blood 82:2273, 1993
20. MacKinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation-separation of graft-versus-host leukemia responses from graft-versus-host disease. Blood 86:1261, 1995
21. Giralt S, Hester J, Huh Y, et al: CD8+ depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Graft vs leukemia without graft vs host disease. Blood 84:538a, 1994 (abstr, suppl 1)
22. Giralt S, Champlin R: Leukemia relapse after allogeneic bone marrow transplant: A review. Blood 83:3603, 1994
23. Mrsic M, Horowitz MM, Atkinson K, et al: Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 9:269, 1992
24. Higano CS, Raskind WH, Singer JW: Use of α interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 80:1437, 1992
25. Giralt S, Escudier S, Kantarjian H, et al: Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 329:757, 1993
26. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382, 1987
27. McGlave P, Arthur D, Haake R, et al: Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. J Clin Oncol 5:1033, 1987
28. Kantarjian HM, Dixon D, Keating MJ, et al: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61:1441, 1988
29. Clift R, Buckner C, Thomas E, et al: Marrow transplantation for patients in accelerated phase of chronic rayeloid leukemia. Blood 84:4368, 1994
30. Majlis A, Kantarjian H, Smith T, et al: What is the significance of cytogenetjc clonal evolution in patients with Philadelphia chromosome positive chronic myelogenous leukemia. Blood 84:150a, 1994 (abstr, suppl 1)
31. Kantarjian H, Smith T, O'Brien S, et al: Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann Intern Med 122:254, 1995
32. Dowding C, Guo Ai-Pu, Osterholz I, et al: Interferon-α over-rides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78:499, 1991
33. Giralt S, Kantarjian H, Talpaz M, et al: Effect of prior interferon alpha therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055, 1993
34. Zuffa E, Bandini G, Bonini A, et al: Outcome of allogeneic transplant in CML patients previously treated with alpha-interferon. Analysis in a single institution. Bone Marrow Transplant 15:S18, 1995 (suppl 2)
35. Shepherd P, Richards S, Allan N: Survival after allogeneic bone marrow transplantation (BMT) in patients randomized into a trial of IFN-α versus chemotherapy: No significant adverse effect of prolonged IFN-α administration. Blood 86:94a, 1995 (abstr, suppl 1)
36. Beelen DW, Graeven U, Elmaagacli AH, et al: Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85:2981, 1995
37. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan N: Unrelated donor marrow transplantation for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543, 1993
38. Beatty P, Anasetti C, Hansen J, et al: Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effect of mismatching for one HLA locus. Blood 81:249, 1993
39. Talpaz M, Kantarjian H, McCredie K, et al: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314:1065, 1986
40. Talpaz M, Kantarjian H, Kurzrock R, Trujillo J, Gutterman J: Interferon alpha produces sustained cytogenetic responses in Philadelphia positive chronic myelogenous leukemia. Ann Intern Med 114:532, 1991
41. Kantarjian H, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M: Chronic myelogenous leukemia: A concise updata. Blood 82:691, 1993
42. Alimena G, Morra E, Lazzarino, et al: Interferon alpha-2b as therapy for Ph′-positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration. Blood 72:642, 1989
43. Ozer H, George S, Schiffer C, et al: Prolonged subcutaneous administration of recombinant alfa-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82:2975, 1993
44. Mahon F, Montastruc M, Faberes C, Reiffers J: Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated in chronic myelogenous leukemia patients treated with recombinant interferon-α. Blood 84:3592, 1994
45. Tura S, Baccarani M, Zuffa E, for the Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
46. Tura S, Baccarani M: Interferon alpha-2a for chronic myeloid leukemia. N Engl J Med 331:402, 1994
47. Hehlmann R, Heimpel H, Hasford J, et al: Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064, 1994
48. Allan N, Richards S, Shepard P, et al: UK-Medical Research Council randomized, multicenter trial of interferon-α n 1 for chronic myeloid leukemia-improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995
49. Ohnishi K, Ohno R, Tomonaga M, et al: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906, 1995
50. Sokal J, Leong S, Gomez G: Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer 59:197, 1987
51. Robertson MJ, Tantravahi R, Griffin JD, Canellos GP, Cannistra SA: Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol 43:95, 1993
52. Kantarjian H, Keating M, Estey E, et al: Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low dose cytarabine. J Clin Oncol 10:772, 1992
53. Arthur CK, Ma DDF: Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol 89:15, 1993 (suppl 1)
54. Guilhot F, Lamagnere J, Harousseau J, et al: A multicenter study of a randomized therapeutic protocol in previously untreated patients with Ph′-positive chronic myelogenous leukaemia: Interferon alfa-2b and hydroxyurea with or without cytosine arabinoside, preliminary results. Eur J Cancer 27:S26, 1991 (suppl 4)
55. Heubner P, Willemze R, Ganser A, et al: YNK01, an oral ara-C derivative in patients with AML, MDS, low-grade malignant NHL and CML. Blood 81:302a, 1994 (abstr, suppl 1)
56. Sacchi S, Kantarjian H, O'Brien S, et al: Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13:2401, 1995
57. Schofield J, Robinson W, Murphy J, Rovira D: Low doses of interferon-α are as effective as higher doses in inducing remission and prolonging survival in chronic myeloid leukemia. Ann Intern Med 121:736, 1994
58. Freund M, von Wussow P, Diedrich H, et al: Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72:350, 1989
59. Anger B, Porzolt F, Leichte R, Heinze B, Bartram C, Heimpel H: A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 58:275, 1989
60. Seong DC, Kantarjian HM, Ro JY, et al. Hypermetaphase fluorescent in situ hybridization for quantitative monitoring of Philadelphia chromosome positive cells in patients with chronic myelogenous leukemia during treatment. Blood 86:2343, 1995
61. Kantarjian HM, Vellekoop L, McCredie KB, et al: Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3:192, 1985
62. Kantarjian HM, Talpaz M, Keating MJ, et al: Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myeloge-nous leukemia. Cancer 68:1201, 1991
63. Simonsson B, Oberg G, Kollander A, et al: Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia (CML). Bone Marrow Transplant 14:S55, 1994 (suppl 3)
64. Carella AM, Frassoni F, Negrin RS: Autografting in chronic myelogenous leukemia - New questions. Leukemia 9:365, 1995
65. Kantarjian HM, Talpaz M, Hester J, et al: Collection of peripheral blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J Clin Oncol 13:553, 1995
66. Chalmers EA, Franklin IM, Kelsey S, et al: Mobilization of Ph-negative peripheral blood stem cells in CML with idarubicin and cytaragine. Bone Marrow Transplant 14:34, 1994 (suppl 3)
67. O'Brien S, Kantarjian H, Keating M, et al: Homoharringtonine therapy induces long-term responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86:3322, 1995
68. O'Brien S, Kantarjian H, Feldman E, et al: Sequential homoharringtonine and interferon produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive chronic myelogenous leukemia. Proc Am Soc Clin Oncol 14:336, 1995 (abstr)
69. O'Brien SG, Goldman J: Current approaches to hemopoietic stem-cell purging in chronic myeloid leukemia. J Clin Oncol 13:541, 1995
70. Brito-Babapulle F, Bowcock SJ, Marcus RE, et al: Autografting for patients with chronic myeloid leukaemia in chronic phase: Peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Haematol 73:76, 1989
71. Kantarjian H, Talpaz M, Andersson B, et al: High doses of cyclophosphamide, etoposide, and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant 14:57, 1994
72. McGlave PB, De Fabritis P, Deisseroth A, et al: Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343:1486, 1994
73. Reiffers J, Goldman JM, Meloni JM, et al: Autologous stem cell transplantation in chronic myelogenous leukemia. A retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 14:407, 1994
74. Hoyle C, Gray R, Goldman J: Autografting for patients with CML in chronic phase: An update. Br J Haematol 86:76, 1994
75. Khouri IF, Kantarjian HM, Talpaz M: High-dose chemotherapy and unpurged autologous stem cell transplantation for chronic myelogenous leukemia: The M.D. Anderson experience. Blood 84:537a, 1994 (abstr, suppl 1)
76. Barnett MJ, Eaves CJ, Phillips GL, et al: Autografting with cultured marrow in chronic myeloid leukemia. Results of a pilot study. Blood 84:724, 1994
77. Carlo Stella C, Mangoni L, Piovani G, et al: In vitro marrow purging in chronic myelogenous leukemia. Effect of mafosfamide and recombinant granulocyte-macrophase colony-stimulating factor. Bone Marrow Transplant 8:265, 1991
78. McGlave PB, Arthur D, Miller WJ, et al: Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 6:115, 1990
79. Verfaillie CM, Miller WJ, Boylan K, et al: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003, 1992
80. van Denderen J, ten Hacken P, Berendes P, et al: Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias. Leukemia 6:1107, 1992
81. Kirkland MA, O'Brien SG, McDonald C, et al: BCR-ABL antisense purging in chronic myeloid leukaemia. Lancet 342:614, 1993 (letter)
82. Ratajczak MZ, Hijiya N, Catani L, et al: Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 79:1956, 1992
83. Luger SM Ratajczak MZ, Stadtmauer EA, et al: Autografting for chronic myeloid leukemia (CML) with C-MYB antisense oligodeoxynucleotide purged bone marrow. A preliminary report. Blood 84:151a, 1994 (abstr, suppl 1)
84. De Fabritiis P, Lisci E, Montefusco M, et al: Autograft after in vitro purging with BCR-ABL antisense oligonucleotides for patients with CML in advanced phase. Bone Marrow Transplant 14:S80, 1994 (suppl 3).
85. Gewirtz A: Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides. Bone Marrow Transplant 14:S57, 1994 (suppl 3)
86. Talpaz M, Kantarjian H, Khouri I, et al: Diploid cells collected from chronic myelogenous leukemia patients during recovery from conventional dose induced myelosuppression generate complete cytogenetic remissions after autologous transplantation. Blood 84:537a, 1994 (abstr. suppl 1)
87. Brenner MK, Rill DR, Moen RC, et al: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85, 1993
88. Etkin M, Filaccio M, Ellerson D, et al: Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther 3:137, 1992
89. Deisseroth AB, Zu Z, Claxton D, et al: Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068, 1994
90. Rowe J, Ryau H, Nilsson BL, et al: Chronic myelogenous leukemia treated with autologous bone marrow transplantation followed by Roquiminex. Blood 84:204a, 1994 (abstr, suppl 1)
91. Kernan NA, Bartsch G, Ash RC: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328:593, 1993
92. Beatty PG, Mori M, Milford E, et al: Racial differences in histocompatibility, implications for unrelated donor BMT. J Cell Biochem 8b:49, 1994 (suppl 1)